NCT04181333 2026-04-14
Safety and Efficacy of Trastuzumab BS
Pfizer
Completed
Clinical Trials
331 trialsNCT04822350 2026-04-02
AVENANCE
Pfizer
Completed
NCT06221397 2026-03-16
LEGIT_MC_EVCDA
AI Labs Group S.L
Completed
NCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT05529979 2026-01-06
SaFE
Quantum Surgical
Completed
NCT04317599 2026-01-02
CAPSTAN CRC
Pierre Fabre Medicament
Completed
NCT04307134 2025-12-31
Besponsa Post Marketing Surveillance Study
Pfizer
Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT04369053 2025-12-26
PREEMPT CRC
Freenome Holdings Inc.
Completed
NCT06462014 2025-12-11
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Pfizer
Completed
NCT04671615 2025-12-10
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
Pfizer
Completed
NCT04735367 2025-12-09
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
Pfizer
Completed
NCT05923112 2025-12-05
BESPONSA Injection 1 mg Special Investigation
Pfizer
Completed
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT04941768 2025-11-28
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT05643885 2025-10-20
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
Pfizer
Completed
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT05599334 2025-10-06
NEAR
Pierre Fabre Medicament
Completed
NCT04272216 2025-09-09
RAVI Registry
Terumo Medical Corporation
Completed
NCT05549232 2025-07-23
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hemanext
Completed
NCT02533258 2025-07-16
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Pfizer
Completed
NCT06115681 2025-07-10
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Boehringer Ingelheim
Completed
NCT03159195 2025-07-01
IRIS
Pfizer
Completed
NCT06307457 2025-06-29
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
Pfizer
Completed
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT04609319 2025-05-31
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Pfizer
Completed
NCT05735652 2025-05-30
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
Boston Scientific Corporation
Completed
NCT03611543 2025-05-21
Evaluating Image Quality and Comfort of an Investigational Curved Paddle Compared to a Standard Paddle
Hologic, Inc.
Completed
NCT04034056 2025-05-09
URBAN
Hoffmann-La Roche
Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed
NCT03464045 2025-04-20
Empa PASS on Urinary Tract Malignancies
Boehringer Ingelheim
Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT05093426 2025-04-03
PERSONAL - Sleep In Breast Cancer
Closed Loop Medicine
Completed
NCT05431777 2025-04-01
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT05650164 2025-03-28
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05166135 2025-03-25
LOYAL
Pfizer
Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT04206787 2025-02-28
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Boehringer Ingelheim
Completed
NCT02761187 2025-02-24
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
Terminated
NCT03024866 2025-02-06
Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Xoft, Inc.
Completed
NCT05954546 2025-02-05
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Pfizer
Completed
NCT05597085 2025-02-04
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Pfizer
Completed
NCT05534789 2025-01-20
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Pfizer
Terminated